Article Figures & Data
Figures
- Figure 1 Patient flow
At the time of study closure, 533 (278 + 275) participants had been randomized, of whom 169 (72 + 97) had withdrawn from the study, 110 (55 + 55) had completed the study, and 274 (151 + 123) were still active in the study. The total numbers of participants with at least 2, 3, and 4 years primary outcome data at the time of study conclusion were 296, 152, and 36, respectively. Sixteen participants at one site were excluded from the analysis due to Good Clinical Practice issues identified prior to the interim analysis. Data from one participant enrolled after study closure were also excluded.
- Figure 2 Changes from baseline to each visit in total functional capacity (TFC) and total motor score (TMS), mean ± standard error
(A) TFC for all patients assigned to active creatine and to placebo. (B) TMS for all patients assigned to active creatine and to placebo. In A (primary analysis) and B (supporting analysis), the 2 track curves track closely except at the final point where the data are sparse (see text for details).
Tables
Data Supplement
Neurology® data supplements are not copyedited before publication. Published editorials and translations have been copyedited.
© 2017 American Academy of Neurology.
Files in this Data Supplement:- Table e-1 - PDF
Coinvestigators
Neurology® data supplements are not copyedited before publication. Published editorials and translations have been copyedited.
© 2017 American Academy of Neurology.
Files in this Data Supplement:- Coinvestigators - Microsoft Word file
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Use of Whole-Genome Sequencing for Mitochondrial Disease Diagnosis
Dr. Robert Pitceathly and Dr. William Macken
► Watch
Topics Discussed
Alert Me
Recommended articles
Clinical manifestations of intermediate allele carriers in Huntington disease
Clinical manifestations of homozygote allele carriers in Huntington disease
Evidence-based guideline: Pharmacologic treatment of chorea in Huntington disease
A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease